Overview

Durvalumab in DLBCL After Autologous Transplant

Status:
Withdrawn

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital Inselspital, Berne

Collaborator:

Celgene

Treatments:

Antibodies, Monoclonal
Durvalumab